Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions

Posted On 2021-01-07 13:21:34

A deeper understanding of innate/acquired resistance to the different TKIs already available for clinical use and the development of new effective treatment strategies to overcome it, represent a current area of intense investigation and has been extensively debated within different papers published in the series.

Editorial on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions
Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?
Francesco Passiglia, Silvia Novello

Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
Bing Xia, Misako Nagasaka, Viola W. Zhu, Sai-Hong Ignatius Ou, Ross A. Soo

How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?
Simon Ekman

Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
Fabrizio Tabbò, Maria Lucia Reale, Paolo Bironzo, Giorgio V. Scagliotti

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
Ibiayi Dagogo-Jack, Lauren L. Ritterhouse

Decade in review: a new era for RET-rearranged lung cancers
Noura J. Choudhury, Alexander Drilon

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
Alessandro Russo, Andrés F. Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo

Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
Janna Josephus Anna Oda Schoenmaekers, Marthe Sentijna Paats, Anne-Marie Clasina Dingemans, Lizza Elisabeth Lucia Hendriks

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
Kenichi Suda, Tetsuya Mitsudomi

Future perspectives from lung cancer pre-clinical models: new treatments are coming?
Francesca Bersani, Deborah Morena, Francesca Picca, Alessandro Morotti, Fabrizio Tabbò, Paolo Bironzo, Luisella Righi, Riccardo Taulli

Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas
Matthias S. Matter, Obinna Chijioke, Spasenija Savic, Lukas Bubendorf

Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review
Ana Ortega-Franco, Virginia Calvo, Fabio Franco, Mariano Provencio, Raffaele Califano

Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
Gianmarco Leone, Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, Silvia Novello

How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease
Lorenza Landi, Federico Cappuzzo

The series “Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Drs. Silvia Novello and Francesco Passiglia served as the unpaid Guest Editors for the series.